ProMIS Neurosciences (NASDAQ:PMN) Announces Earnings Results

ProMIS Neurosciences (NASDAQ:PMN) released its quarterly earnings data on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports.

ProMIS Neurosciences Stock Performance

Shares of PMN opened at $0.56 on Monday. The firm has a market capitalization of $18.44 million, a P/E ratio of -5.75 and a beta of 0.02. The stock has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.84. ProMIS Neurosciences has a 52 week low of $0.47 and a 52 week high of $2.37.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PMN shares. Guggenheim reiterated a “buy” rating and set a $6.00 price objective on shares of ProMIS Neurosciences in a research report on Tuesday, April 1st. Maxim Group initiated coverage on ProMIS Neurosciences in a research report on Monday. They issued a “buy” rating and a $3.00 target price on the stock.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.